

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Semaphorin 4A in direct ELISAs. In direct ELISAs, 50%-100% cross-reactivity with recombinant human (rh) Semaphorin 4C and rhSemaphorin 4G is observed, and less than 5% cross-reactivity with rhSemaphorin 4B, 4D, and recombinant mouse Semaphorin 4A is observed.
Source	Monoclonal Mouse IgG ₁ Clone # 741531
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Semaphorin 4A Gly32-His683 Accession # Q9H3S1
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	Human peripheral blood monocytes

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

Semaphorin 4A (Sema4A, previously semB) is a Class 4 transmembrane Semaphorin with activity in the immune and nervous systems (1). The 761 amino acid (aa) human Sema4A precursor contains a 32 aa signal sequence, a 651 aa extracellular domain (ECD) containing sema, PSI and C2-type immunoglobulin domains, a 21 aa transmembrane domain, and a 57 aa cytoplasmic domain with two Ser/Thr phosphorylation sites (2). Human Sema4A ECD shares 87%, 87%, 86% and 85% aa identity with mouse, rat, bovine and canine Sema4A, respectively, and shares 32-37% aa identity with other human Sema4 family members. Of six reported splice variants with 723, 629, 370, 321, 236 and 220 aa, five lack the N-terminus and/or portions of the sema domain, and three lack the transmembrane and cytoplasmic domains in the C-terminus (3). Sema4A was first described as a molecule that enhances T cell activation and interacts with TIM-2 (T cell immunoglobulin and mucin domain-2) (4). Mice with targeted disruption of Sema4A show defects in dendritic cell-mediated T cell priming and Th1 responses (5). Roles for Sema4A have also been identified in the brain, the endothelium and the eye. It mediates hippocampal neuron growth cone collapse *in vitro* through interaction of the sema domain with Plexin-B1 (6). Interaction of Sema4A with endothelial cell Plexin-D1 causes opposition to the angiogenic, proliferative, chemotactic and integrin-mediated adhesive actions of VEGF (7). The retina of Sema4A^{-/-} mice shows severe degeneration, and mutations of Sema4A are associated with retinitis pigmentosa and cone rod dystrophy in humans (8, 9).

References:

1. Kumanogoh, A. *et al.* (2003) *J. Cell Sci.* **116**:3463.
2. Swissprot Accession # Q9H3S1.
3. Entrez Accession # CAI15528, CAI15529, CAI15531, CAI15532, CAI15533 and EAW52993.
4. Kumanogoh, A. *et al.* (2002) *Nature* **419**:629.
5. Kumanogoh, A. *et al.* (2005) *Immunity* **22**:305.
6. Yukawa, K. *et al.* (2005) *Int. J. Mol. Med.* **16**:115.
7. Toyofuku, T. *et al.* (2007) *EMBO J.* **26**:1373.
8. Rice, D.S. *et al.* (2004) *Invest. Ophthalmol. Vis. Sci.* **45**:2767.
9. Abid, A. *et al.* (2007) *J. Med. Genet.* **43**:378.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc. and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.